X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with JINDAL SOUTHWEST H - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs JSW HOLDINGS - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES JSW HOLDINGS INDOCO REMEDIES/
JSW HOLDINGS
 
P/E (TTM) x 22.0 31.2 70.6% View Chart
P/BV x 2.6 2.9 89.3% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 INDOCO REMEDIES   JSW HOLDINGS
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
JSW HOLDINGS
Mar-14
INDOCO REMEDIES/
JSW HOLDINGS
5-Yr Chart
Click to enlarge
High Rs360635 56.7%   
Low Rs249250 99.6%   
Sales per share (Unadj.) Rs119.039.0 304.9%  
Earnings per share (Unadj.) Rs8.429.7 28.2%  
Cash flow per share (Unadj.) Rs15.229.7 51.3%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7652.4 10.8%  
Shares outstanding (eoy) m92.1511.10 830.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.611.3 22.6%   
Avg P/E ratio x36.414.9 244.4%  
P/CF ratio (eoy) x20.014.9 134.3%  
Price / Book Value ratio x4.30.7 635.2%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,0834,914 571.5%   
No. of employees `0006.0NA 301,800.0%   
Total wages/salary Rs m2,16720 10,998.5%   
Avg. sales/employee Rs Th1,817.0216,650.0 0.8%   
Avg. wages/employee Rs Th359.09,850.0 3.6%   
Avg. net profit/employee Rs Th127.7164,800.0 0.1%   
INCOME DATA
Net Sales Rs m10,968433 2,531.2%  
Other income Rs m400-   
Total revenues Rs m11,007433 2,540.4%   
Gross profit Rs m1,565410 381.8%  
Depreciation Rs m6330 316,400.0%   
Interest Rs m620-   
Profit before tax Rs m909410 222.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m13980 173.4%   
Profit after tax Rs m771330 233.8%  
Gross profit margin %14.394.6 15.1%  
Effective tax rate %15.319.5 78.1%   
Net profit margin %7.076.1 9.2%  
BALANCE SHEET DATA
Current assets Rs m5,725105 5,470.4%   
Current liabilities Rs m5,4548 71,764.5%   
Net working cap to sales %2.522.4 11.0%  
Current ratio x1.013.8 7.6%  
Inventory Days Days620-  
Debtors Days Days7246 154.6%  
Net fixed assets Rs m5,3071 589,708.9%   
Share capital Rs m184111 166.0%   
"Free" reserves Rs m6,3316,737 94.0%   
Net worth Rs m6,5167,242 90.0%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9707,259 164.9%  
Interest coverage x15.6NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.1 1,535.1%   
Return on assets %7.04.5 153.2%  
Return on equity %11.84.6 259.9%  
Return on capital %12.45.7 219.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886300 295.4%  
From Investments Rs m-1,706-301 566.4%  
From Financial Activity Rs m1,316NA-  
Net Cashflow Rs m497-1 -49,660.0%  

Share Holding

Indian Promoters % 59.2 60.9 97.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.5 2,500.0%  
FIIs % 6.0 7.8 76.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 30.8 72.7%  
Shareholders   12,805 29,821 42.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   IL&FS INV. MANAGERS  REDINGTON (INDIA)  NALWA SONS INV  REPCO HOME  IIFL HOLDINGS  



Today's Market

Sensex Extends Losses; Pharma Stocks Top Losers(Closing)

After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


May 21, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - NALWA SONS INV COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS